Firebrick Pharma Ltd has released a press release.
Appendix 4E & Annual Report FY23
Filed with ASX ·
6ix hasn’t read this filing yet.
Firebrick Pharma Limited on 6ix
Story so far
Earlier from Firebrick Pharma
- Response to ASX Price and Volume Query
- Firebrick Phase 3 Trial Closes with 500 Subjects
- Firebrick Covid-19 Trial Achieves Primary Endpoint
- June 2023 Quarterly Activity Report & Appendix 4C
- Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment
Later from Firebrick Pharma
- Phase 3 Common Cold Trial Results
- Update on Nasodine Trial and Forward Plans
- September 2023 Quarterly Activity Report & Appendix 4C
- Firebrick Receives $1.81m R&D Tax Incentive
- Firebrick Investor Update
Follow Firebrick Pharma into a list and get an email when it puts out news.
Follow Firebrick Pharma